Klostenal (Beclometasone Dipropionate)

Beclometasone Dipropionate binds to intracellular glucocorticoid receptors, forming a complex that enters the cell nucleus and alters gene transcription. This suppresses the production of pro‑inflammatory cytokines, chemokines, and adhesion molecules while enhancing anti‑inflammatory proteins, leading to decreased leukocyte infiltration and reduced inflammation in the rectal mucosa.

The dosage of Klostenal is determined by the prescribing clinician based on the severity of the condition, patient age, and response to therapy. The prescriber will specify the amount, frequency, and duration of rectal administration, and patients should follow the written instructions without altering the regimen.

Safety of rectal Beclometasone Dipropionate during pregnancy or lactation has not been fully established. Healthcare providers should evaluate the potential benefits against possible risks, and the drug should only be used if deemed necessary. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To request Klostenal, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Klostenal’s active ingredient, Beclometasone Dipropionate, is a potent glucocorticoid with high local anti‑inflammatory activity and limited systemic absorption when used rectally. Compared with older agents such as hydrocortisone, it offers stronger receptor affinity and may achieve symptom control at lower doses, potentially reducing the risk of systemic side effects. Choice of therapy depends on clinical judgment and patient response.

Klostenal should be stored at room temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Ensure the container is tightly closed when not in use, and keep it out of reach of children. Do not freeze or expose the product to extreme temperatures, as this may affect its stability.

Klostenal is administered rectally, typically as a suppository or enema, according to the prescriber’s instructions. The patient should insert the dose into the rectum, preferably after a bowel movement and before lying down, to allow optimal contact with the mucosa. Hand hygiene before and after administration is recommended to maintain sterility.

The most serious risks include adrenal suppression with prolonged use, severe allergic reactions such as anaphylaxis, and rectal bleeding or ulceration. Systemic corticosteroid effects, such as hyperglycemia, increased infection susceptibility, and bone density loss, may also occur if significant absorption happens. Patients should be monitored for these signs and report any concerning symptoms promptly.

Klostenal should be avoided in individuals with known hypersensitivity to Beclometasone Dipropionate or any excipients in the formulation. It is also contraindicated in patients with active untreated infections of the rectum, uncontrolled systemic fungal infections, or those receiving systemic corticosteroids where additive effects could be harmful. Pregnant or lactating women should only use it after a risk‑benefit assessment by a physician.